Trevi Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Trevi Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Trevi Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$14.1M, a 55.7% decline year-over-year.
  • Trevi Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$48.2M, a 52.4% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$33.9M, a 13.4% decline from 2022.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$29.9M, a 7.91% increase from 2021.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$32.5M, a 0.04% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$33.9M -$4.02M -13.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-20
2022 -$29.9M +$2.57M +7.91% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-20
2021 -$32.5M +$13K +0.04% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$32.5M -$5.84M -21.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$26.6M -$8.24M -44.7% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$18.4M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.